Total Live Articles: 383

Chlamydia

NICE CKS Chlamydia – uncomplicated genital. Last revised Feb 2025.

BASHH Chlamydia 2015. Last updated Sep 2018.

UK Health Security Agency Guidance NCSP: programme overview. Last updated Jun 2021.

Background Information

Aetiology

Chlamydia is caused by the infection of the obligate intracellular bacterium Chlamydia trachomatis

Epidemiology

Chlamydia is the most commonly reported curable bacterial STI in the UK

Risk factors include:

  • <25 y/o
  • New sexual partner
  • >1 sexual partner in the last year
  • Lack of consistent condom use

Clinical Features

Genital Infection

Chlamydia is asymptomatic in ~70% of women and ~50% of men

Women
  • Increased vaginal discharge
  • Mucopurulent cervicitis +/- contact bleeding
  • Post-coital / intermenstrual bleeding
  • Deep dyspareunia
  • Dysuria
  • Lower abdominal pain
  • Cervical motion tenderness
Men Symptoms in men can be very mild

  • Urethral discharge (mucoid / mucopurulent)
  • Dysuria
  • Urethral discomfort

Extra-Genital Infection (Less Common)

Rectal chlamydia Usually asymptomatic

If symptomatic: anal discharge and anorectal discomfort

Chlamydia conjunctivitis Unilateral chronic low-grade conjunctival irritation (may be bilateral)
Oropharyngeal infection Usually asymptomatic

If symptomatic: pharyngitis and sore throat

Complications

Possible complications include:

Chlamydia infection in pregnancy is associated with adverse outcomes, including:

  • Increased risk of premature rupture of membranes, pre-term delivery, and low birth weight in the infant
  • Increased risk of intra-partum pyrexia and late post-partum endometritis
  • Infections of the eyes, lungs, nasopharynx, and genitals in the neonate (much more serious compared to adults)

Diagnosis

Screening

According to the National Chlamydia Screening Programme (NCSP), the following should be offered a chlamydia test:

  • Partner with chlamydia or symptoms of chlamydia infection
  • All sexually active women <25 y/o (to be tested yearly and after having sex with a new partner)
  • All sexually active women <25 y/o who attend a sexual health service / contraception service / termination of pregnancy service

Chlamydia Testing

Test of choice: NAAT

Sample collection methods:

  • Male: first pass urine (alternative: urethral swab)
  • Female: vulvovaginal swab (alternative: endocervical swab or first pass urine)

Cultures are NOT taken routinely to diagnose chlamydia, unlike in gonorrhoea (see the Gonorrhoea article for more details).

Management

Refer ALL patients to GUM clinic / local specialist for management.

General Advice

Abstain from all sexual activity until 7 days after they and their partner(s) have completed treatment

Pharmacological Management

  • 1st line: oral doxycycline 100mg BD for 7 days
  • 2nd line: oral azithromycin 1g OD for 1 day followed by 500mg OD for 2 days
  • 3rd line: oral erythromycin

Management in Pregnant Patients

  • Discuss with GUM and specialist
  • Safe antibiotic options include: azithromycin, erythromycin, amoxicillin
  • Test of cure is routinely needed in pregnant patients

Doxycycline is contraindicated in pregnancy and breastfeeding.

Partner Notification

Partner notification period:

  • If symptomatic men → notify all partners within the past 4 weeks (1 month) (or most recent partner if more than 4 weeks ago)
  • If all other patients (i.e. asymptomatic men and women) → notify all partners within the past 6 months

Management of sexual contacts:

  • Any sexual partner who tests positive for Chlamydia trachomatis should receive treatment
  • Offer full STI screening, including HIV testing (and hepatitis B screening and vaccination if indicated)

Chlamydia infection has a high frequency of transmission, with concordance rates of up to 75% of partners being reported.

The partner notification period for chlamydia is 2x that of gonorrhoea

In gonorrhoea:

  • Symptomatic men → 2 week lookback (vs 4 weeks in chlamydia)
  • All other patients (i.e. asymptomatic men and women) → 3-month lookback (vs 6 months in chlamydia)

Follow Up

Test of Cure

Test of cure is NOT routinely recommended.

Exceptions:

  • Pregnant patients
  • Poor compliance
  • Persistent symptoms

Test of cure should be performed at least 3 weeks after completion of treatment.

Repeat Testing

Indications:

  • Offer to all <25 y/o diagnosed with chlamydia, 3-6 months after completion of treatment
  • Consider if >25 y/o who are at high risk of re-infection

References



Share Your Feedback Below

Disclaimer

We’re actively expanding Guideline Genius to cover the full UKMLA content map. Therefore, you may notice some conditions not uploaded yet, or articles that currently focus on diagnosis and management for now.

We are also continuously reviewing and updating existing content to ensure accuracy and alignment with current guidelines. Some earlier articles are undergoing revision as part of this process. Once all content has been fully reviewed, this will be clearly communicated on the platform.

For updates, follow us on Instagram @guidelinegenius.

We welcome any feedback or suggestions via the anonymous feedback box at the bottom of each article and will do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD

Be first to accessour QBank

Sign up to receive major guideline updates and early access when we launch.